PROVIREX Genome Editing Therapies GmbH
PrivateLast Round
VC Round
Aug 20, 2026
Total Funding Raised
$1.96M
Momentum
Top 5%
of companies Caplight tracks
Company Overview
PROVIREX Genome Editing Therapies GmbH is a biotechnology company that develops advanced therapy medicinal products (ATMPs) using proprietary recombinase-based genome editing technology to excise integrated viral DNA for the treatment of HIV and other viral infections.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery, Precision Medicine, Clinical Trials
Business Model
B2B
Customer Profile
Services & Consulting
AI Layer
Non-AI
Keywords
Historical Pricing
Historical view of private secondary pricing and transaction trends.
PROVIREX Genome Editing Therapies GmbH Comparables
Compare PROVIREX Genome Editing Therapies GmbH with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Seamless Therapeutics | 82% | |
| Excision BioTherapeutics | 81% | |
| American Gene Technologies | 79% |
PROVIREX Genome Editing Therapies GmbH Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| VC Round | Aug 20, 2026 | ||||
| Grant | Jul 29, 2025 | ||||
| Series A | Oct 27, 2022 | ||||
| Seed | Nov 29, 2019 |
Key People
Founding team and executive leadership
PROVIREX Genome Editing Therapies GmbH Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Ascenion | Seed |
| InnoVentureFonds | VC Round |
| BioVenture | VC Round, Series A |
| IFB Hamburg | Grant |
Market signals
Structured signals derived from secondary market and firmographic data.
- Sep 14, 2026
Grew 19% QoQ, from 16 to 19 employees.
- Aug 20, 2026
$7M round with InnoVentureFonds and BioVenture
PROVIREX Genome Editing Therapies GmbH Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Request accessFrequently Asked Questions
Common questions about PROVIREX Genome Editing Therapies GmbH's valuation, stock price, and market status.
Is PROVIREX Genome Editing Therapies GmbH a public or private company?
PROVIREX Genome Editing Therapies GmbH is a private company.
What is the current stock price of PROVIREX Genome Editing Therapies GmbH?
PROVIREX Genome Editing Therapies GmbH is a private company with no public stock price. Caplight tracks PROVIREX Genome Editing Therapies GmbH's secondary market activity and provides MarketPrice™ estimates to Caplight users.
How much is PROVIREX Genome Editing Therapies GmbH worth (valuation)?
Valuation information for PROVIREX Genome Editing Therapies GmbH is not publicly available.
Can I buy PROVIREX Genome Editing Therapies GmbH stock?
PROVIREX Genome Editing Therapies GmbH shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors. Visit https://www.caplight.com to learn more.
When was PROVIREX Genome Editing Therapies GmbH's last funding round?
PROVIREX Genome Editing Therapies GmbH's most recent funding round was VC Round on August 20, 2026.
Who are the main investors in PROVIREX Genome Editing Therapies GmbH?
Key investors in PROVIREX Genome Editing Therapies GmbH include BioVenture.
Will PROVIREX Genome Editing Therapies GmbH IPO soon?
No public IPO plans have been announced for PROVIREX Genome Editing Therapies GmbH.
How can I track PROVIREX Genome Editing Therapies GmbH secondary market activity?
Caplight tracks bids, offers, and trades for private companies. Visit https://www.caplight.com to monitor PROVIREX Genome Editing Therapies GmbH's secondary market activity and sign up for updates.